Locations:
NeuroTherapia, a Cleveland Clinic Innovations portfolio company, has been awarded its second grant from the Alzheimer's Association Part the Cloud program. The grant will fund the clinical development of NTRX-07, a first-of-its-kind drug for Alzheimer's disease (AD) treatment.
NeuroTherapia, a clinical-stage pharmaceutical company, recently announced that it has been awarded a grant from the Alzheimer's Association Part the Cloud program. The grant is intended to support the development of NTRX-07, a drug being developed by NeuroTherapia for the treatment of Alzheimer's disease. The Alzheimer's Association grant will aid in the clinical development of NTRX-07, which has demonstrated encouraging results in preclinical studies and in a small group of Alzheimer's disease patients in a Phase 1 study. This was done through the help of the Alzheimer's Drug Discovery Foundation, Cleveland Clinic, Brain Trust Accelerator Fund II and Dolby Family Ventures.
NTRX-07 is a unique drug that targets neuroinflammation, a critical element of Alzheimer's disease. It holds the capability to slow, or possibly freeze, the progression of this debilitating disease. Tony Giordano, CEO of NeuroTherapia, expressed his excitement about receiving the grant from Part the Cloud and their support in the development of NTRX-07. He emphasized the company's commitment to developing innovative treatments for Alzheimer's disease.
Joseph Foss, MD, Chief Medical Officer for NeuroTherapia, explained that NTRX-07 represents a new approach to treating Alzheimer's disease by addressing the neuroinflammation that contributes to brain damage. As an orally administered drug, NTRX-07 has shown a good safety profile at doses anticipated to be effective in the recently completed Phase 1 safety studies. The upcoming Phase 2a study is expected to broaden the understanding of NTRX-07 in Alzheimer's disease patients and may provide early insights into its effects. This study is designed to demonstrate safety, tolerability and biological activity.
Heather Snyder, PhD, Alzheimer's Association vice president of medical and scientific relations, highlighted the importance of strategic research funding to diversify the drug pipeline. She expressed the Alzheimer's Association's excitement to “support promising early-stage clinical trials, such as this one, to accelerate the transition of findings from the laboratory into potential treatments.”
This is the second grant that NeuroTherapia has received. The company has also received venture funding from the Alzheimer's Drug Discovery Foundation, Cleveland Clinic, Brain Trust Accelerator Fund II, and Dolby Family Ventures. This funding has enabled the company to complete Phase 1 clinical trials and position itself for the upcoming Phase 2a trial.
Read the full article via PRNewswire.
Search